Supplementary Tables S1-S3 from Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302)

Supplementary Tables S1-S3. Supplementary Table S1: Changes in tumor deposition in the control and cyclophosphamide-treated groups as measured by PET/CT. Supplementary Table S2: Effects of cyclophosphamide on HER2 expression, collagen type I deposition and vascular parameters in BT474-M3 tumors. Supplementary Table S3. Reagents for immunofluorescence on FFPE and frozen tumor sections